
From: eddie.gibson@bms.com on behalf of Eddie Gibson [eddie.gibson@bms.com]
Sent: 25 October 2005 10:15
To: Cathryn Fuller
Cc: Nina Pinwill; Meindert Boysen; Sarah Garner; Maria Gibson
Subject: Re: Technology Appraisal - Drug misuse naltrexone - SUBMISSION OF EVIDENCE
Attachments: Card for Eddie Gibson <eddie.gibson@bms.com>

Dear Cathryn,

My apologies, I did not realise that we had not informed you that we would not submit evidence in this case. Our decision to not submit is based on our belief that all evidence is in the public domain and that we cannot add substantially to the body of evidence available. We would, however, welcome the opportunity to comment on the various documents and the interpretation of the evidence as the technology appraisal progresses.

Regards,

Eddie Gibson

----- Original Message -----

From: Cathryn Fuller <Cathryn.Fuller@nice.org.uk>

Date: Tuesday, October 25, 2005 9:54 am

Subject: Technology Appraisal - Drug misuse naltrexone - SUBMISSION OF EVIDENCE

> Dear Dr Gibson

>

> Please note that the closing date for invited submissions for the
> technology appraisal of Naltrexone as a treatment for relapse
> prevention in drug misusers
> was 5.00pm on Friday 21 October 2005.

>

> As this deadline has now passed and we have not received any
> correspondence from yourself, please could you confirm in a letter
> or by
> email to the Institute that your company will not be submitting
> evidence for this technology appraisal.

>

> For information, your company was invited to take part in this
> technology appraisal on 27 June 2005.

>

> I look forward to hearing from you shortly.

>

> Kind regards

>

> Cathryn Fuller

> Technology Appraisals Project Manager

>> National Institute for Health and Clinical Excellence (NICE)

26/06/2006

> > MidCity Place
> > 71 High Holborn
>

Delivered via MessageLabs
